RedHill Biopharma has partnered with Hyloris Pharmaceuticals to develop and sell a drug called RHB-102 (Bekinda) worldwide, except for North America. This drug is designed to help with nausea and vomiting for cancer patients and those with digestive issues. RedHill will receive an initial payment and could earn up to $60 million in additional payments from Hyloris, as well as a share of future sales, outside of Canada, Mexico, and the US.
Hyloris will handle the drug’s development, regulatory approval, and marketing. RedHill aims to get approval from the US FDA. The drug, in 12mg and 24mg doses, is a once-daily pill that provides 24-hour relief. The UK has given positive feedback, which might lead to the drug being the first of its kind for treating nausea and vomiting caused by chemotherapy and radiotherapy.
RedHill has also completed US studies showing the drug’s effectiveness for other conditions like acute gastroenteritis. Additionally, RedHill received $1.7 million from the US government to further develop another drug, opaganib.